RxCelerate acquires specialist bioanalytical CRO Total Scientific Ltd

The out-sourced drug development company, RxCelerate Ltd, announced today that it has completed the acquisition of Cambridge-based specialist bioanalytical contract research organisation, Total Scientific Ltd.

RxCelerate, which has offices in Cambridge, MA and Cambridge, UK, provides bespoke drug development services to clients ranging from virtual biotech companies to global pharmaceutical giants. Its unique model is built around out-sourcing drug development expertise rather than practical experimental work, allowing RxCelerate to guide projects from discovery through to the clinic as efficiently as possible.

Total Scientific was founded in 2006, on the Babraham Research Campus, and specialises in measuring complex drugs and proteins in biological samples, compliant with Good Laboratory Practice (GLP).

“Total Scientific was the first company in the world to offer Phenome-wide Association Studies (PheWAS) as a commercial service, underpinning their status as global leaders in highly specialised bioanalysis” said Dr Jill Reckless, CEO of RxCelerate. “This capability, coupled with their GLP-compliant bioanalysis platform significantly extends the range of cutting-edge capabilities available to our clients to move their projects more efficiently to the next value inflection point.”

Dr David Mosedale, Founder and Chief Scientist at Total Scientific, said “We built a fantastic team at Total Scientific over the last ten years, who have solved many challenging problems for our clients. But the opportunity to become part of the RxCelerate group with their global reach into US markets, allowing even more drug developers to benefit from services like PheWAS, which we have pioneered, was simply too good to pass up.”

Total Scientific currently has 11 employees, bringing the total staff at RxCelerate to 37. The Total Scientific brand will be retired with immediate effect, with all services continuing to be offered through RxCelerate. Existing clients will be contacted directly, but will see no changes in the delivery of their projects during the transition. No financial details of the transaction have been released.

“RxCelerate is one of the fastest growing companies in the UK” said Founder and Chairman, Dr David Grainger. “Adding the unique capabilities of Total Scientific to the platform will further cement our reputation as a global leader in out-sourced drug development.”

Read More News